Pharma companies are increasingly using technologies like mobile apps and chatbots to directly reach out to patients, through creating awareness on disease and helping them in adhering to treatment regimen.
Lupin, India's third-largest drug maker on November 23 said it has launched a chatbot for disease awareness.Named as ‘ANYA’ the first bot of its kind to be launched in India, is
specially designed to provide medically verified information aimed at answering patient queries related to ailments.
ANYA will initially address queries related to diabetes.
The chatbot was launched at the 46th Annual Meeting of the Research Society for the Study of Diabetes.
Recent research suggests India is estimated to have had 72 million cases of diabetes in 2017 and the figure is expected to almost double to 134 million by 2025.
“At Lupin, we continue to explore ways to integrate technology to support effective patient care. Chatbot as a technology has enormous potential to aid in medical assistance and to support in building awareness and breaking myths associated with various therapies," said Rajeev Sibal, President - India Region Formulation (IRF), Lupin.
"This will also be a significant step in providing better access in rural markets as we adopt and launch digital healthcare platforms for better outreach,” Sibal added.
Pharma companies are increasingly using technologies like mobile apps and chatbots to directly reach out to patients, through creating awareness on disease and helping them in adhering to the treatment regimen.
Sun Pharma earlier developed a mobile app called RespiTrack, that allows monitoring of asthma attacks, symptoms and medications prescribed by the physician. Cipla too launched the Breathfree app as a one-stop destination for all the information related to chronic airway diseases.Lupin said their chatbot provides reliable disease-management information for patients from comprehensive sources.